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Objective: catheter directed thrombolysis has been advocated for complete and rapid dissolution of iliofemoral deep venous
thrombosis (DVT). The aim of our study is to compare, in a randomised trial, local thrombolysis and anticoagulation with
anticoagulation alone in patients with iliofemoral DVT.
Methods: a consecutive series of 35 eligible patients, were randomised to either catheter directed thrombolysis followed by
anticoagulation or to anticoagulation alone. Clot lysis and deep venous reflux were assessed with ultrasound duplex and
plethysmography after 6 months.
Results: complete data were available in the 18 and 17 patients randomised to thrombolysis and anticoagulation,
respectively. At 6 months, patency rate was better in cases treated with thrombolysis [13/18 (72%) vs 2/17 (12%),
p5 0.001]. Venous reflux was higher in-patients treated with anticoagulant [7 patients (41%) vs 2 (11%), p 0.04].
Conclusion: in the short-term patients treated with catheter directed thrombolysis obtained better patency and competence
than those treated with standard anticoagulation.
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Systemic anticoagulants have been the cornerstone of
DVT therapy since 1960s.1 They provide prophylaxis
against further thrombus formation during which
the body's fibrinolytic system can lyse smaller
venous thrombi. This has been proved to be successful
in recanalization of the majority (95%) of popliteo-
tibial thromboses.2 In contrast, only a minority of
iliofemoral thromboses (20%) can be completely
recanalized.3 The rate of canalisation appears to be
important determinant of valvular competence.4,5
The combination of obstruction and valvular incom-
petence will increase ambulatory venous pressure6
which correlates with the severity of post-thrombotic
syndrome.7 During the last decade few studies have
suggested that catheter directed thrombolysis for
iliofemoral DVT preserves valve function and reduces
the incidence of post phlebitic syndrome.1,8±11This paper was presented at ESVS 2001 annual meeting in
Lucerne, Switzerland.
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study comparing thrombolysis with anticoagulant in
Iliofemoral DVT. Here we report the preliminary
results based on 6 months follow-up.
Patients and Methods
We enrolled a consecutive series of patients admitted
to Suez Canal University hospital since 1 April 2000
with iliofemoral DVT who complied with the follow-
ing inclusion criteria:
(1) Patients have iliofemoral venous thrombosis
documented with colour duplex and/or ascend-
ing venography.
(2) Patients have no significant co-morbidity or term-
inal illness that makes life expectancy less than
6 months.
(3) No contraindication to thrombolysis (surgery
within 14 days, history of CVA or CNS disease,
history of major GI bleeding within 1 year, severe
hypertension (4180/100), known or suspected
pregnancy etc).l rights reserved.
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(5) DVT is acute (less than 10 days history).
Patients were randomised to either thrombolysis
followed by anticoagulant or anticoagulant alone.
Heparin was discontinued 2 h before randomisation
for patients already receiving intravenous heparin.
The randomisation was achieved by computer desig-
nated cards assigning patients to either groups.
Patients randomised to anticoagulant had a standard
regimen of heparin (an initial bolus of 5000 U, followed
by a continuous infusion adjusted to maintain partial
thromboplastin time twice the normal control value).12
Warfarin was started the same evening to maintain
a target International Normalised Ratio of 2.0.
Patients' randomised to catheter directed throm-
bolysis had pulse spray thrombolysis followed by
anticoagulant.
Technique of Thrombolysis
We used ipsilateral popliteal approach as a vascular
access. Streptokinase (Kabikinase, KABI) was used as
a thrombolytic agent. We started with pulse spray (Jet
lysis catheter, Angiomed, Bard) and assessed the pro-
gress at approximately 15 min intervals by injecting
contrast through the catheter. By about 1 h the patient
had usually received about 1 million units and there
was usually a considerable clearing of most of the
thrombus.
We progressed to further thrombolysis using low
dose infusion (100 000 units per hour) (Fig. 1). Patients
were returned to the radiology department at 12 h
intervals for phlebography and catheter advancement
if necessary. Thrombolytic therapy was terminated
when there was complete lysis, no progress after 12 h
or any major complications.
Outcome
The imaging study used for initial DVT dia-
gnosis (duplex ultrasonagraphy or venography) was
repeated 24±48 h after randomisation and again before
hospital discharge. Study end points were defined as
follows: complete lysis (100% lysis of all detachable
thrombus in the iliofemoral segment), partial lysis
(part of the thrombus was lysed) and no lysis. Images
were compared and assessed by a vascular imaging
panel that was blinded to randomisation assignment.
The panel was unaware of the sequencing of the
studies and therefore did not know whether images
were obtained at baseline, 24±48 h after randomisa-
tion, or before discharge. All patients were monitoredEur J Vasc Endovasc Surg Vol 24, September 2002daily for evidence of gross haematuria, haematemesis,
or melaena. Serial haematocrits were obtained so that
clinically inapparent bleeding could be identified.
Median length of hospital stay from study enrol-
ment to discharge; mortality rate and major complica-
tions (bleeding, pulmonary embolism, etc) were
recorded.
Follow up of the trial was undertaken at 6 weeks
then 3 and 6 months.
Venous function was checked at 6 months using the
following:
(1) Colour duplex  venography to monitor the evolu-
tion of the thrombi and the appearance of the
reflux after acute DVT.4,5,13,14
(2) Photoplethysmography for evaluation of venous
reflux by measuring the venous reflux time
(VRT).15 If it is short (520 s), the test is repeated
after inflating a narrow cuff at the ankle to occlude
the superficial veins. Failure of the cuff to normal-
ise the RT suggests deep venous or perforator
incompetence.
(3) Air-plethysmography. For evaluation of venous
outflow (VO). The outflow fraction at 1 s (OF1)
is the VO expressed as a percentage of the total
venous capacity An OF1 of 438% is considered
indicative of the absence of any functional
obstruction, a range of 30±38% indicates mod-
erate obstruction, and 530% indicates severe
obstruction.16
Any further intervention required as a result of the
follow up appointment would also be recorded.
Statistical analysis
Based on an expected patency rate of 70% vs 20% in
patients treated with thrombolysis and with anticoa-
gulation, respectively, a significance level of 5% and a
power of 90% we estimated the necessary sample size
to be 24. We decided that at least 30 patients should be
randomised, allowing for six patients to be lost to
follow-up. Baseline characteristics in both groups
were compared with the use of the Student's t-test
for continuous variables that were normally distribu-
ted. Comparison between the anticoagulant group
and thrombolysis group was analysed using Chi-
square with Yates' correction for dichotomous vari-
ables. If there were two cells with expected counts
less than 5.0, two-tailed Fisher's exact test was used.
A p value of 50.05 was selected as the criterion
denoting significance. All statistical analyses were
performed with the aid of statistical analysis software,
Minitab for windows except Fisher's Exact test which
Fig. 1. Thrombolysis of extensive DVT involving popliteal, femoral and iliac veins. Top right; after 15 min of pulse spray thrombolysis. Top
left; after 30 min of pulse spray thrombolysis. Bottom right; 1 h of pulse spray thrombolysis. Bottom left; 24 h of low dose infusion
thrombolysis.
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Illinosis, U.S.A.).
Results
During the study period from 1 April 2000 to 1 April
2001, 207 patients with DVT diagnosed by ultrasono-
graphy were screened, and 35 patients were enrolled,17 had anticoagulant and 18 had thrombolysis.
Reasons for exclusion are presented in Table 1. No
significant differences were seen between treatment
arms in baseline characteristics (Table 2). The throm-
bolysis group received a total dose of streptokinase
2±4.5 million units (average 2.9 million units) per
patient. Patency of the iliofemoral segment 1 week
after treatment was better in the thrombolysis group
(Table 3). Median length of stay was 5.5 days in theEur J Vasc Endovasc Surg Vol 24, September 2002
Table 1. Reasons for study non-enrolment.
Reason No. of patients
(n 172)
Recent surgery within 14 days 87 (47%)
Symptoms 410 days 25 (13%)
History of major GI bleeding 11 (6%)
Patient refusal 7 (4%)
Anaemia (haematocrit 525%) or
thrombocytopenia (5100 000/mm)
7 (4%)
Patients 470 years old 7 (4%)
Terminal illness 7 (4%)
History of major GU bleeding 6 (3%)
History of CVA or CNS disease 5 (3%)
Isolated calf DVT 5 (3%)
Severe hypertension (4180/110) 3 (2%)
Pregnancy 2 (1%)
CVA: Cerebrovascular accident; CNS: central nervous system;
GI: gastrointestinal; GU: genitourinary.






Female gender 12 (71%) 12 (67%) 1.00







3 days 6 days 0.14
Occlusive thrombus 16 (94%) 14 (78%) 0.98
Current or previous cancer 2 (12%) 2 (11%) 1.00
Previous PE or DVT 5 (29%) 3 (17%) 0.64
Recent surgery
(14±60 days)
0 1 (6%) 0.47
Extent of thrombus
Iliofemoral 5 (29%) 6 (33%) 0.8
Femoral 12 (71%) 12 (67%)




1 week 0 11 (61%) 50.001
6 months 2 (12%) 13 (72%) 50.001
Incomplete lysis
1 week 0 7 (39%) 0.004
6 months 8 (47%) 5 (28%) 0.238
No lysis
1 week 17 (100%) 0 50.001
6 months 7 (41%) 0 50.001
Fig. 2. Wall stent inserted in the left iliac vein from the contralateral
femoral vein.
Table 4. Venous functions after 6 months of the treatment.
Anticoagulant Thrombolysis p-value
No obstruction or reflux 2 (12%) 13 (72%) 50.001
Moderate obstruction 5 (29%) 4 (22%) 0.627
Severe obstruction 10 (59%) 1 (6%) 0.001
Reflux (obstruction) 7 (41%) 2 (11%) 0.042
212 M. Elsharawy and E. Elzayatanticoagulant group and 7 days in the thrombolysis
group (p 0.43).
One patient in the anticoagulant group had symp-
tomatic pulmonary embolism (6%). Three patients in
the thrombolysis group had high fever (17%). There
was no major bleeding or death.
Clot lysis on repeat imaging study at 6 months was
significantly better in the thrombolysis group (Table 3).
Venous outflow and deep venous reflux were signifi-
cantly better in the thrombolysis group (Table 4).Eur J Vasc Endovasc Surg Vol 24, September 2002In one case the DVT was caused by May±Thurner
syndrome and after near complete clot dissolution
with thrombolysis, the residual left common iliac
vein narrowing was treated by means of angioplasty
and placement of Wallstent endoprosthesis (Fig. 2).
Discussion
Several studies have shown that 50±82% of patients
with iliofemoral DVT who were treated with anti-
coagulant alone went on to suffer from the post
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agents has been studied before. Systemic rUK has
been shown to be no more effective than heparin in
achieving clot lysis in small dose.19 High dose sys-
temic thrombolysis results in a significantly better
short- and long-term clinical outcome than conven-
tional heparin/anticoagulation therapy but at the
expense of a serious increase in major bleeding and
pulmonary emboli.20±24 The use of loco-regional
thrombolysis (infusing the thrombolytic agent in a
dorsal foot-vein of the affected leg while the leg was
kept tightly bandaged) demonstrated significantly
fewer clinical symptoms of post-thrombotic syn-
drome.25 However, the induction of local fibrinolysis
without systemic effects, has not, however, been
achieved.26 A recent systematic review has shown
that there is no evidence that there is a difference in
efficacy between thrombolytic agents or that local
therapy differs from systemic therapy.27 Repeated
bolus (systemic) urokinase has promising efficacy
and safety. However its efficacy against anticoagula-
tion alone was not confirmed.28
Catheter-directed thrombolytic therapy has been
studied recently and has been shown to be safe and
effective in achieving early and intermediate-term
venous patency.9,29±34 These series showed patency
60±83% after 6 months compared to 72% in the present
study.
Another advantage of catheter-directed thromboly-
sis of iliofemoral vein thrombosis that it reveals many
anatomical abnormalities e.g. May±Thurner syn-
drome that may predispose to thrombosis and are
often amenable to stenting.35,36
The ipsilateral popliteal venous approach is pre-
ferred because it is often difficult to penetrate an
occluded superior ilio-femoral vein from the internal
jugular vein or the contralateral common femoral
vein, and venous valves may prevent safe catheterisa-
tion. This approach also clears the distal veins.37
Streptokinase is currently the only thrombolytic
regimen approved by the Food and Drug Administra-
tion for the treatment of DVT, but its administration
is often fraught with bleeding complications and
rigors.19 In an overview of previous trials, major
bleeding complications were 2.9 times greater with
streptokinase than with heparin alone.38
In the present study streptokinase followed by
heparin was as safe as standard intravenous heparin
for the management of proximal DVT. The absence of
any bleeding complication, major or minor, in the
streptokinase group was unexpected. We attribute
the safety of this regimen to the short duration of
the streptokinase infusion and strict adherence to
exclusion criteria.Our findings also showed that thrombolysis was
appropriate for only a small subset of patients treated
with DVT. In this study only 17% of screened patients
treated with DVT were eligible for thrombolytic
therapy. This is consistent with previous surveys of
patients treated with DVT.19,39,40 In all these series,
recent surgery was the most frequent factor preclud-
ing thrombolytic therapy followed by symptoms 410
days in the present study and history of CVA or CNS
disease in the others.
Conclusions
This report represents the first trial of catheter direc-
ted thrombolysis-using streptokinase versus heparin
alone for treatment of IVT. The early result of the trial
has showed that catheter directed thrombolysis was
better than anticoagulant. However a longer follow up
and a bigger number are required to confirm this
policy.
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